A Girl with Bone Sclerosis and Fracture

Nilika Wijeratne,1,2,3* Kay Weng Choy,1 Zhong Xian Lu,1,2,4 Justin Brown,5,6 and James C.G. Doery1,2

1 Department of Pathology and 5 Monash Children’s Hospital, Monash Health, Clayton, Victoria, Australia; Departments of
2 Medicine and 4 Pediatrics, Monash University, Clayton, Victoria, Australia; 3 Dorevitch Pathology, Heidelberg, Victoria, Australia;
4 Melbourne Pathology, Collingwood, Victoria, Australia.

* Address correspondence to this author at: Dorevitch Pathology, Department of Biochemistry, 18 Banksia St. Heidelberg, Vic, 3084
Australia. Fax +61-3-9244-0207; e-mail nilika.wijeratne@monash.edu.

CASE DESCRIPTION

A previously fit and well 5-year-old girl presented to the emergency department with right hip pain and limp following a minor fall from play equipment. X-ray imaging confirmed the presence of a femoral fracture as well as diffuse sclerosis in the sacrum, pelvis, and bilateral proximal femurs (Fig. 1). MRI scan revealed mild stenosis of auditory canals, optic canals, and foramen magnum with no neural compression. DEXA (dual energy X-ray absorptiometry) scan showed markedly increased bone density, with a total body age-matched z score of +14. Bone marrow aspirate was normal. The patient had no other significant medical history and she was not on any regular medications. There was no family history of note but her mother also has increased bone mineral density.

Results for serum electrolytes, urea, creatinine, total calcium, phosphate, parathyroid hormone, vitamin D, alkaline phosphatase, and alanine aminotransferase were all within reference intervals. However, other biochemistry investigations revealed aspartate aminotransferase (AST) 89 U/L (reference interval, 20–80 U/L); lactate dehydrogenase (LD) 667 U/L (reference interval, 100–200 U/L); acid phosphatase (ACP) 32.1 U/L (reference interval, <6.5 U/L), with tartrate-resistant ACP 29.9 U/L (reference interval, 1.2–4.4 U/L); creatine kinase (CK) 615 U/L (reference interval, <190 U/L); CK-MB activity by immunoinhibition technique 760 U/L (reference interval, <10 U/L); CK isoenzymes by electrophoresis, CK-MB <3% (reference interval, <6%) and CK-BB 87% (reference interval, <1%). Complete blood examination was normal except mildly low hemoglobin of 10.1 g/dL (reference interval, 11.5–15.5 g/dL).

QUESTIONS TO CONSIDER

• What conditions may cause diffuse sclerotic bone lesions?
• What is the most probable diagnosis for this girl?
• How do you explain the discrepancy between the CK-MB activity measured by the immunoinhibition method and the CK isoenzyme electrophoresis results?

Final Publication and Comments

The final published version with discussion and comments from the experts will appear in the May 2016 issue of Clinical Chemistry. To view the case and comments online, go to http://www.clinchem.org/content/vol62/issue5 and follow the link to the Clinical Case Study and Commentaries.
Educational Centers
If you are associated with an educational center and would like to receive the cases and questions 1 month in advance of publication, please email clinchem@aacc.org.

All previous Clinical Case Studies can be accessed and downloaded online at https://www.aacc.org/publications/clinical-chemistry/clinical-case-studies/2016-clinical-case-studies

AACC is pleased to allow free reproduction and distribution of this Clinical Case Study for personal or classroom discussion use. When photocopying, please make sure the DOI and copyright notice appear on each copy.

AACC is a leading professional society dedicated to improving healthcare through laboratory medicine. Its nearly 10,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. AACC brings this community together with programs that advance knowledge, expertise, and innovation. AACC is best known for the respected scientific journal, Clinical Chemistry, the award-winning patient-centered web site Lab Tests Online, and the world’s largest conference on laboratory medicine and technology. Through these and other programs, AACC advances laboratory medicine and the quality of patient care.